DK0595873T3 - Negativt cytosindeaminaseselektionssystem til gentransferteknikker og -terapier - Google Patents
Negativt cytosindeaminaseselektionssystem til gentransferteknikker og -terapierInfo
- Publication number
- DK0595873T3 DK0595873T3 DK92915347T DK92915347T DK0595873T3 DK 0595873 T3 DK0595873 T3 DK 0595873T3 DK 92915347 T DK92915347 T DK 92915347T DK 92915347 T DK92915347 T DK 92915347T DK 0595873 T3 DK0595873 T3 DK 0595873T3
- Authority
- DK
- Denmark
- Prior art keywords
- cytosine deaminase
- therapies
- negative
- gene transfer
- selection system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Devices For Checking Fares Or Tickets At Control Points (AREA)
- Brushes (AREA)
- Exchange Systems With Centralized Control (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/725,076 US5358866A (en) | 1991-07-03 | 1991-07-03 | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
PCT/US1992/005385 WO1993001281A1 (en) | 1991-07-03 | 1992-06-30 | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0595873T3 true DK0595873T3 (da) | 2000-07-10 |
Family
ID=24913069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92915347T DK0595873T3 (da) | 1991-07-03 | 1992-06-30 | Negativt cytosindeaminaseselektionssystem til gentransferteknikker og -terapier |
Country Status (12)
Country | Link |
---|---|
US (2) | US5358866A (da) |
EP (1) | EP0595873B1 (da) |
JP (1) | JP3386461B2 (da) |
AT (1) | ATE191505T1 (da) |
AU (1) | AU667820B2 (da) |
CA (1) | CA2112395C (da) |
DE (1) | DE69230882T2 (da) |
DK (1) | DK0595873T3 (da) |
ES (1) | ES2152929T3 (da) |
GR (1) | GR3033909T3 (da) |
SG (1) | SG52475A1 (da) |
WO (1) | WO1993001281A1 (da) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6337209B1 (en) | 1992-02-26 | 2002-01-08 | Glaxo Wellcome Inc. | Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
CA2042093C (en) * | 1990-05-09 | 2002-12-24 | Gyula Hadlaczky | Cell line carrying an excess of mammalian centromeres |
US6555370B1 (en) * | 1990-11-13 | 2003-04-29 | Immunex Corporation | Bifunctional selectable fusion genes |
US5358866A (en) * | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
WO1993010218A1 (en) * | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
FR2683725B1 (fr) * | 1991-11-15 | 1995-07-07 | Pasteur Institut | Composition cellulaire pour le traitement des organismes humains ou animaux. |
DK0637966T3 (da) * | 1992-05-01 | 1998-05-04 | Us Health | Tumoricid terapi med "tilskuer-virkning" |
JPH09500783A (ja) * | 1993-05-21 | 1997-01-28 | ターゲッティッド ジェネティクス コーポレイション | シトシンデアミナーゼ(cd)遺伝子に基づく二機能性選択融合遺伝子 |
CA2189543A1 (en) * | 1994-05-02 | 1995-11-09 | Lawrence A. Loeb | Thymidine kinase mutants |
US6451571B1 (en) | 1994-05-02 | 2002-09-17 | University Of Washington | Thymidine kinase mutants |
US6013517A (en) | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
AU2585395A (en) | 1994-05-09 | 1995-11-29 | Chiron Corporation | Retroviral vectors having a reduced recombination rate |
US5856153A (en) * | 1994-11-17 | 1999-01-05 | Cayla | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases |
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US20020068049A1 (en) * | 1998-09-10 | 2002-06-06 | Henderson Daniel R. | Tissue specific adenoviral vectors |
EP0857212A2 (en) * | 1995-10-23 | 1998-08-12 | Board Of Regents, The University Of Texas System | Methods and compositions comprising glut-2 and glut-2 chimeras |
DE19704979A1 (de) * | 1996-02-07 | 1997-08-14 | Max Delbrueck Centrum | Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen |
US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US20030033617A1 (en) * | 1996-04-10 | 2003-02-13 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US20020160970A1 (en) * | 1996-04-10 | 2002-10-31 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6077697A (en) * | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6566089B1 (en) * | 1996-09-04 | 2003-05-20 | Tularik Inc. | Cell-based drug screens for regulators of gene expression |
CN1303436A (zh) | 1998-02-19 | 2001-07-11 | 圣朱迪儿童研究医院 | 致敏和抑制人肿瘤细胞生长的组合物和方法 |
GB9810752D0 (en) * | 1998-05-19 | 1998-07-15 | Glaxo Group Ltd | Cystosine deaminase gene |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
US7186409B2 (en) * | 1998-08-14 | 2007-03-06 | The Children's Medical Center Corporation | Neural stem cells and use thereof for brain tumor therapy |
US20020115213A1 (en) * | 1998-08-14 | 2002-08-22 | Northeastern Ohio Universities Of Medicine | Engraftable neural progenitor & stem cells for brain tumor therapy |
FR2794025A1 (fr) * | 1999-05-25 | 2000-12-01 | Transgene Sa | Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere |
US8716558B2 (en) | 1999-06-30 | 2014-05-06 | Marker Gene Technologies, Inc. | Method of altering glycosylation of proteins in response to nojirimycin glucuronide in a plant cell expressing glucuronidase |
US6656917B1 (en) * | 1999-06-30 | 2003-12-02 | Marker Gene Technologies, Inc. | Compositions and methods for targeted enzymatic release of cell regulatory compounds |
AU4744201A (en) * | 2000-03-15 | 2001-09-24 | Childrens Medical Center | Systemic gene delivery vehicles for the treatment of tumors |
US6579522B1 (en) * | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
AU1844702A (en) * | 2000-09-28 | 2002-04-08 | Bioriginal Food And Science Co | Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof |
EP1264891A1 (en) * | 2001-05-31 | 2002-12-11 | Plant Research International B.V. | Modification of plant genomes by inducible site-specific recombination of transgenes |
ATE481497T1 (de) * | 2001-08-01 | 2010-10-15 | Univ Utah | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a |
US20030086903A1 (en) * | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
DE50310378D1 (de) * | 2002-07-26 | 2008-10-02 | Basf Plant Science Gmbh | Neue selektionsverfahren |
US20040149174A1 (en) * | 2003-02-05 | 2004-08-05 | Mbt Holding Ag | Accelerating admixture for concrete |
US7534585B2 (en) | 2003-07-21 | 2009-05-19 | Transgene S.A. | Multifunctional cytokines |
CA2532783C (en) | 2003-07-21 | 2013-09-17 | Transgene S.A. | Polypeptide having an improved cytosine deaminase activity |
EP1687032B1 (en) * | 2003-11-14 | 2010-02-24 | Genvec, Inc. | Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc). |
US20080039328A1 (en) * | 2004-03-17 | 2008-02-14 | Basf Plant Science Gmbh | Post Harvest Control of Genetically Modified Crop Growth Employing D-Amino Acid Compounds |
US20080050819A1 (en) * | 2004-03-17 | 2008-02-28 | Basf Plant Science Gmbh | Constructs for Marker Excision Based on Dual-Function Selection Marker |
CN1997746B (zh) | 2004-05-26 | 2012-09-26 | 普西奥克瑟斯医疗有限公司 | 用于治疗癌症的嵌合腺病毒 |
EP2163635B1 (en) | 2004-08-02 | 2013-05-22 | BASF Plant Science GmbH | Method for isolation of transcription termination sequences |
CN101198701B (zh) | 2005-04-19 | 2013-04-24 | 巴斯福植物科学有限公司 | 单子叶植物中的淀粉胚乳特异性和/或萌芽胚特异性表达 |
US20070026012A1 (en) | 2005-08-01 | 2007-02-01 | Cornell Research Foundation, Inc. | Compositions and methods for monitoring and altering protein folding and solubility |
US9150850B2 (en) | 2005-08-22 | 2015-10-06 | Cornell Research Foundation, Inc. | Compositions and methods for analyzing protein interactions |
AU2008214568B2 (en) | 2007-02-16 | 2013-04-18 | Basf Plant Science Gmbh | Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants |
US20090196854A1 (en) * | 2008-02-04 | 2009-08-06 | Kytos Biosystems S.A. | Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery |
CN105624193B (zh) | 2008-09-26 | 2021-07-13 | 索元生物医药(美国)有限公司 | 重组载体 |
EP2248903A1 (en) | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
WO2013095071A2 (ko) * | 2011-12-21 | 2013-06-27 | 씨제이제일제당 (주) | L-라이신 생산능을 갖는 미생물을 이용하여 l-라이신을 생산하는 방법 |
EP3473708B1 (en) | 2012-07-24 | 2021-01-27 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
EA036414B1 (ru) | 2013-10-25 | 2020-11-09 | Псайоксус Терапьютикс Лимитед | Онколитические аденовирусы, содержащие трансгены |
EP3082834B1 (en) | 2013-12-11 | 2020-03-11 | The General Hospital Corporation DBA Massachusetts | Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors |
ES2768715T3 (es) | 2014-04-10 | 2020-06-23 | Transgene | Vectores oncolíticos poxvíricos |
EP3283529B1 (en) | 2015-04-17 | 2023-06-07 | The General Hospital Corporation | Agents, systems and methods for treating cancer |
EP3288573B1 (en) | 2015-04-30 | 2020-02-12 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a b7 protein |
SG11201805136TA (en) | 2015-12-17 | 2018-07-30 | Psioxus Therapeutics Ltd | Group b adenovirus encoding an anti-tcr-complex antibody or fragment |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
SG11201901715UA (en) | 2016-08-29 | 2019-03-28 | Psioxus Therapeutics Ltd | Adenovirus armed with bispecific t cell engager (bite) |
KR102371151B1 (ko) | 2020-03-13 | 2022-03-07 | 주식회사 큐로셀 | 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
CA2018273C (en) * | 1989-06-09 | 1999-04-06 | Peter D. Senter | Thermally stable cytosine deaminase |
GB8919607D0 (en) * | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
US5358866A (en) * | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
-
1991
- 1991-07-03 US US07/725,076 patent/US5358866A/en not_active Expired - Lifetime
-
1992
- 1992-06-30 DE DE69230882T patent/DE69230882T2/de not_active Expired - Fee Related
- 1992-06-30 WO PCT/US1992/005385 patent/WO1993001281A1/en active IP Right Grant
- 1992-06-30 CA CA002112395A patent/CA2112395C/en not_active Expired - Fee Related
- 1992-06-30 ES ES92915347T patent/ES2152929T3/es not_active Expired - Lifetime
- 1992-06-30 SG SG1996005053A patent/SG52475A1/en unknown
- 1992-06-30 EP EP92915347A patent/EP0595873B1/en not_active Expired - Lifetime
- 1992-06-30 AU AU22959/92A patent/AU667820B2/en not_active Ceased
- 1992-06-30 JP JP50225093A patent/JP3386461B2/ja not_active Expired - Fee Related
- 1992-06-30 AT AT92915347T patent/ATE191505T1/de not_active IP Right Cessation
- 1992-06-30 DK DK92915347T patent/DK0595873T3/da active
-
1994
- 1994-07-07 US US08/271,874 patent/US5624830A/en not_active Expired - Lifetime
-
2000
- 2000-07-05 GR GR20000401594T patent/GR3033909T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0595873A4 (en) | 1994-12-07 |
ATE191505T1 (de) | 2000-04-15 |
JPH07501925A (ja) | 1995-03-02 |
AU2295992A (en) | 1993-02-11 |
US5358866A (en) | 1994-10-25 |
DE69230882T2 (de) | 2000-11-09 |
DE69230882D1 (de) | 2000-05-11 |
ES2152929T3 (es) | 2001-02-16 |
SG52475A1 (en) | 1998-09-28 |
CA2112395A1 (en) | 1993-01-21 |
CA2112395C (en) | 2008-04-22 |
WO1993001281A1 (en) | 1993-01-21 |
EP0595873B1 (en) | 2000-04-05 |
EP0595873A1 (en) | 1994-05-11 |
AU667820B2 (en) | 1996-04-18 |
US5624830A (en) | 1997-04-29 |
JP3386461B2 (ja) | 2003-03-17 |
GR3033909T3 (en) | 2000-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0595873T3 (da) | Negativt cytosindeaminaseselektionssystem til gentransferteknikker og -terapier | |
EP0500917A4 (en) | Recombinant herpes simplex viruses vaccines and methods | |
DK0506945T3 (da) | Fremgangsmåde til genoverførsel under anvendelse af retrotransposoner | |
EP0846160A4 (en) | METHODS TO INCREASE THE PRODUCTION OF VIRAL VACCINE IN CELL CULTURE BY SUPPRESSING INTERFERON | |
DE60303810D1 (de) | Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen | |
ATE270342T1 (de) | Endosomolytisch wirksame partikel | |
DK0863202T3 (da) | Rekombinant Sendai-virus | |
DK160998C (da) | Plasmid indeholdende dna fra en plasmidfraktion af b.thuringiensis, e.coli bakteriestamme indeholdende plasmidet, gensplejset e.coli bakteriestamme, fremgangsmaade til fremstilling af plasmidet, fremgangsmaade til at skabe en gensplejset e.coli bakteriestamme, fremgangsmaade til fremstilling af bacillus thuringiensis krystalprotein og fremgangsmaade til at opnaa insekticid virkning i et miljoe | |
AU8067698A (en) | Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus | |
DK0617736T3 (da) | Anvendelse af Bacillus thuringiensis isolater til bekæmpelse af skadedyr i familien Aphididae | |
ATE365205T1 (de) | Virale partikel, die nach infektion durch humanes cytomegalovirus freigesetzt werden und ihre verwendung als impfstoff | |
ATE342997T1 (de) | Herpesvirus saimiri als viraler vektor | |
Doersen et al. | Cytoplasmic inheritance of erythromycin resistance in human cells. | |
DE60016429D1 (de) | Zell- und/oder tumor-spezifische promotor-abhängige änderung der gezielten expression des herpes gamma 34.5 gens | |
Schuessler et al. | Charge cluster-to-alanine scanning of UL128 for fine tuning of the endothelial cell tropism of human cytomegalovirus | |
Dulbecco | Transformation of cells in vitro by DNA-containing viruses | |
Welsh et al. | Lymphocyte-dependent ‘natural’immunity to virus infections mediated by both natural killer cells and memory T cells | |
ZA200509730B (en) | Archaeon expression system | |
Mullen et al. | Cytosine deaminase negative selection system for gene transfer techniques and therapies | |
AU6262786A (en) | Growing aids virus in cell lines lacking human class ii histocompatability antigens | |
Xiao et al. | Efficient Strategy for Synthesizing Vector-Free and Oncolytic Herpes Simplex Type 1 Viruses | |
GB2300259B (en) | Diagnostic and therapeutic system | |
DK0635061T3 (da) | Fremgangsmåde til begrænsning af genetisk manipulerede organismers overlevelse i deres miljø | |
DK204586A (da) | Hybridceller, der producerer et karakteristisk antigen for hepatitis b-virus, opnaaet ud fra hepatocytter og celler, der er tilvejebragt fra aber, fremgangsmaade til opnaaelse af hybridcellerne og anvendelse af disse til produktion af antigenet | |
WO2000008192A3 (en) | Herpesviral vectors for gene delivery |